Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index; 68 of the 244 sources its claims cite were checked for support.
Abstract
Objective The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus process Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein chole…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends evaluating and treating hypertriglyceridemia with fasting triglyceride measurement, secondary-cause workup, lifestyle therapy for mild-to-moderate elevations, and combined diet plus drug therapy for severe/very severe hypertriglyceridemia to prevent pancreatitis. It also concludes that triglycerides are associated with cardiovascular risk but whether they are causal remains uncertain.
Key findings
- The guideline recommends screening adults with a fasting lipid panel at least every 5 yr (1/QQEE), basing hypertriglyceridemia diagnosis on fasting rather than nonfasting triglycerides (1/QQQE), and against routine lipoprotein particle heterogeneity measurement (1/QQEE).
- It defines moderate hypertriglyceridemia as 200–999 mg/dl, severe as 1000–1999 mg/dl, and very severe as ≥2000 mg/dl; for severe/very severe hypertriglyceridemia (>1000 mg/dl), it recommends combining dietary fat and simple carbohydrate reduction with drug treatment to reduce pancreatitis risk (1/QQQQ), with fibrate as first-line for triglyceride-induced pancreatitis (1/QQQE).
- Lifestyle therapy is recommended initially for mild-to-moderate hypertriglyceridemia (1/QQEE); for moderate hypertriglyceridemia, the treatment goal is a non-HDL cholesterol level in agreement with NCEP ATP guidelines (1/QQEE); statins should not be used as monotherapy for severe or very severe hypertriglyceridemia but may be useful for moderate hypertriglyceridemia to modify cardiovascular risk (1/QQEE).
- In NHANES 1999–2004, 33% of nearly 6000 participants had serum triglycerides ≥150 mg/dl (42% among those aged ≥60 yr); about 14% had 150–200 mg/dl, 16% had 200–500 mg/dl, and about 2% had >500 mg/dl. Meta-analytic estimates included an adjusted odds ratio of 1.72 (95% CI, 1.56–1.90) for coronary heart disease comparing top vs bottom triglyceride tertiles, and an ERFC hazard ratio of 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid factors, reduced to 0.99 (95% CI, 0.94–1.05) after adjustment for HDL and non-HDL cholesterol.
Methods
- The Task Force followed the GRADE approach: strong recommendations use “we recommend” and number 1; weak recommendations use “we suggest” and number 2; evidence quality is denoted QEEE (very low), QQEE (low), QQQE (moderate), and QQQQ (high).
- The guideline was developed by a chair selected by The Endocrine Society Clinical Guidelines Subcommittee, five additional experts, and a methodologist; evidence included observational/epidemiological studies and a systematic review/meta-analysis commissioned by The Endocrine Society.
- Funding was derived solely from The Endocrine Society, and the Task Force received no corporate funding or remuneration.
Limitations
- The Task Force states that it acknowledges the observational nature of the available evidence and dependence on epidemiological studies, and that it made several strong recommendations based on assumptions about patients’ values and preferences.
- The paper states that whether serum triglycerides are causally related to atherosclerosis remains to be elucidated, that elevated triglycerides may sometimes be a marker rather than a causal factor, and that there is a lack of clear human data showing triglyceride reductions reduce cardiovascular disease.
- Stated limitations of specific evidence include lack of standardization and reference levels for nonfasting triglycerides, and for the Copenhagen City Heart Study analysis, a small number of subjects with high triglycerides, no adjustment for HDL cholesterol, and lack of fasting triglyceride levels for comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 24 Not valid · 106 Not checked · 100 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [30] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk., Circulation sourceExperimental — accuracy not yet measured
The introduction (p. 495) reports that the small, dense LDL phenotype was associated with increased myocardial infarction risk, consistent with two previous studies. But the paper does not say that epidemiological studies vary in their findings about an independent association of large or small LDL with cardiovascular disease. Its multivariate analysis examines associations with LDL phenotype, not independent associations with disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35,38,39).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [35] Sacks, 2003, Low density lipoprotein and cardiovascular disease: a reappraisal. (Clinical Review 163)., J Clin Endocrinol Metab source
- Partly supportedcites [38] Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women., Circulation sourceExperimental — accuracy not yet measured
The Results (Association of NMR Lipoproteins, Lipids, and Apolipoproteins with CVD; page unavailable) report that large LDL particles were significantly associated with incident cardiovascular disease in women when all nine particle subclasses were included in the model. They were not associated with cardiovascular disease in the separate adjusted model. The paper does not establish that large LDL specifically predicts atherosclerosis or coronary heart disease. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [39] Campos, 2001, Low density lipoprotein size, pravastatin treatment, and coronary events., JAMA source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40,41).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [40] de Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias., Nat Clin Pract Endocrinol Metab source
- Supportedcites [41] Holewijn, 2010, Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk., J Intern Med source
The Discussion reports that, in this population-based sample, apoB identified people with a compromised cardiovascular risk profile more effectively than non-HDL cholesterol, while LDL cholesterol was least effective. It also reports significantly greater discrimination of prevalent CVD for apoB than for non-HDL cholesterol. The finding is based on this cohort; the authors note that a cited meta-analysis found no difference between apoB and non-HDL cholesterol. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several prospective studies suggest that circulating levels of small, dense LDL particles are better predictors of coronary atherosclerosis, carotid atherosclerosis, and response to therapy than are levels of large, buoyant LDL particles (28,(31)(32)(33).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [28] Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery regression: hepatic lipase-mediated changes in LDL density., Circulation sourceExperimental — accuracy not yet measured
The Abstract reports prospective associations between LDL size or density and coronary artery disease, and says patients with small, dense LDL responded better to therapy than those with large, buoyant LDL. The Results link changes in LDL buoyancy to changes in coronary stenosis. The cited paper does not address carotid atherosclerosis, so it does not support that part of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [31] St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study., Arterioscler Thromb Vasc Biol source
- Not checked — no full text of the sourcecites [32] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)., Atherosclerosis source
- Partly supportedcites [33] Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk., Arterioscler Thromb Vasc Biol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that small and medium LDL particle levels were associated with cardiovascular disease, whereas large LDL particle levels were not significantly related; it also says this pattern agrees with prospective cohorts including a study of carotid atherosclerosis. It does not establish that small, dense LDL levels predict response to therapy better than large LDL levels. Instead, the Discussion proposes evaluating lipoprotein measures in treatment studies as future work. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Prospective studies have indicated that, compared with fasting levels, nonfasting serum triglyceride levels may be a better or similar predictor of CVD events in the general population (15-18).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.2. Evidence
What the sources say
- Not checked — no full text of the sourcecites [15] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women., JAMA source
- Not checked — no full text of the sourcecites [16] Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women., JAMA source
- Supportedcites [17] Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events., Circulation source
The paper’s introductory passage says three studies suggested that nonfasting triglycerides may predict CVD events better than or similarly to fasting levels. Its Results also report a stronger association for nonfasting triglycerides in its prospective cohort of initially healthy women. No page number is available in our copy. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Stalenhoef, 2008, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL., Curr Opin Lipidol source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
149 more claims · 26 with their cited sources checked
Create a free account to see all 283 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 94
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current management strategies for HTG and mixed dyslipidemia provide limited and inconsistent benefits in TG lowering and cardiovascular outcomes, underscoring the need for more effective and durable approaches targeting TRL and apoB-containing lipoproteins (Filtz et al., 2024; Berglund et al., 2012; Chapman et al., 2011).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Berglund et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150 -200 mg/dl), whereas 16% had triglyceride levels of 200 -500 mg/dl, and about 2% had levels above 500 mg/dl.”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“In the National Health and Nutrition Examination Survey (NHANES), 1999 -2004, 33% of the nearly 6000 participants (37% men, 30% women) had serum triglycerides of at least 150 mg/dl (Ն1.7 mmol/liter) (5).”
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 7×
“Cosponsoring Associations: American Heart Association, European Society of Endocrinology.”
InfluentialDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group (1).”
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Research works printed but not linked: 2
- Assmann, 1993, Results and conclusions of the prospective cardiovascular Munster (PROCAM) study, 19
- Brunzell, 2001, Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency, 2789
Cited by
Items 701–800 of 886
Parveen, F. S., Quamri, M. A., Ahmed, K., & Shahid, A. (2022) · International Journal of Advanced Biochemistry Research · doi:10.33545/26174693.2022.v6.i2c.151 · Cited by 1
Pharmacokinetic interaction of rosuvastatin with artichoke (Cynara scolymus L.) leaf extract in rats
Masalmeh, A. M. A., Mallah, E., Mansoor, K., et al. (2023) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2023.116608 · Cited by 1
Pohlmeier, A. M. (2013) · ThinkTech (Texas Tech University) · Cited by 1
Genetics of acute pancreatitis
Lerch, F. U. W. A. M. M. (2016) · doi:10.3998/panc.2016.22 · Cited by 1
Molecular Genetics of Hypertriglyceridaemia
Dron, J. S., & Hegele, R. A. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0026710 · Cited by 2
Kirkegård, J., Cronin-Fenton, D. P., Heide‐Jørgensen, U., & Mortensen, F. V. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.028 · Cited by 1
xu, Y., Shen, H., Shi, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2541801/v1 · Cited by 1
DOSAGE OF CISPLATIN AND RELATED TOXICITY OF CANCER PATIENTS BASED ON BODY FAT AND MUSCLE MASS
Geriņa-Bērziņa, A., Vikmanis, U., Bajinskis, A., et al. (2015)
Optimizing the Effect of ω-3 Fatty Acids on the Lipid Profile in Metabolic Syndrome Patients
Khafagy, G. M., & Ali, M. E. (2015) · European Journal of Preventive Medicine · doi:10.11648/j.ejpm.20150306.13
“Although the primary treatment targets for patients with mild to moderate hypertriglyceridemia is reduction of LDL-C and/or non-high-density lipoprotein cholesterol (non-HDL-C) [7], normal TG levels (<150 mg/dL) is also associated with a reduction in the risk of coronary heart disease [8].”
BackgroundSimvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence
Jimenez, J. G., & Haft, G. (2014) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s50952 · Cited by 1
Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies
Moens, S. J. B., Hassing, C., Nieuwdorp, M., Stroes, E. S. G., & Dallinga‐Thie, G. M. (2013) · Clinical Lipidology · doi:10.2217/clp.13.23
Uso de la plasmaféresis en la pancreatitis aguda hipertrigliceridémica
Pérez-Martínez, D., & Martínez-Quintana, M. E. (2014) · Medicina Intensiva · doi:10.1016/j.medin.2014.10.001
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Miyamoto, L., Egawa, T., Oshima, R., Kurogi, E., Tomida, Y., Tsuchiya, K., & Hayashi, T. (2013)
Case report Abdominal pain in hypertriglyceridemia
Alkimawi, K. A. (2014)
Targets in osteoporosis treatment Metas para o tratamento da osteoporose
Bandeira, F. A. F., Lazaretti‐Castro, M., & Premaor, M. O. (2014)
Icosapent ethyl in hypertriglyceridaemia: a guide to its use
Lyseng-Williamson, K. A., McCormack, P. L., & Kim, E. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0278-5
Castaldo, R. S. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0288-3
“severe (C500 mg/dL) hypertriglyceridaemia, and may be options as add-on therapy to statins in patients with persistently elevated TG levels [4].”
BackgroundJordanov, M. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-11161-2_2
“The triglyceride level ranges from about 250 to 1000 mg/dl in approximately one half of first-degree relatives [19].”
BackgroundKorb, A., Sonnekus, P. H., & Botha, J. (2015) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2015.1118230
Lúcio, D. D. S., & Borghesi, R. A. (2016) · Revista da Faculdade de Ciências Médicas de Sorocaba · doi:10.5327/z1984-4840201625381
Quand demander un bilan génétique devant une hypertriglycéridémie ?
Villard, A., Charrière, S., Filippo, M. D., Marçais, C., & Moulin, P. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30140-7
Case Report: Severe hypertriglyceridemia in a nondiabetic treated with low dose insulin infusion
Tong, C. V., Velaiutham, S., Aziz, N. A., et al. (2015)
Lepira, F. B., Kintoki, V., Makulo, J.-R. R., & Kintoki, F. M. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.611046
“3 mmol/l) increases the risk of pancreatitis [1] [3].”
BackgroundInfluentialConsenso Gallego Multidisciplinar sobre el Uso de Hipolipemiantes
López, B., Díaz, A., Rodríguez, J. M. V., Piñeiro, P. B., Isorna, C. C., Freijomil, A. P., Díaz, J. L. D., Pérez Freijomil, A., Aldana, D. R., & Castro Iglesias, A. (2016) · Galicia Clínica · doi:10.22546/37/1070
RARE CAUSE AND PRESENTATION OF SEVERE HYPERTRIGLYCERIDEMIA.
Awami., A., Alfaraj, S. Z., & Sulaibikh., A. (2017) · International Journal of Advanced Research · doi:10.21474/ijar01/2791 · Cited by 1
Gregory, A., Leung, M., Nussbaumer, G., et al. (2017) · Current Dermatology Reports · doi:10.1007/s13671-017-0175-8
Single-Dose Niacin-Induced Hepatitis
Reines, J. K., & Lagina, A. T. (2018) · Emergency Medicine · doi:10.12788/emed.2018.0082
KLINIKINIS ATVEJIS: HIPERLIPIDEMINIS PANKREATITAS
Gintautas, A., Janušonis, T., & Paškevičiūtė, R. (2017) · Sveikatos mokslai · doi:10.5200/sm-hs.2017.077
Therapeutic plasma exchange for severe hyperlipidaemia in a patient with poorly controlled diabetes
Hermelin, D., Dinarvand, P., Krvavac, A., et al. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224227
VERY SEVERE HYPERTRIGLYCERIDEMIA IN SUSPECTED FAMILIAL CHYLOMICRONEMIA INFANT
Hamka, F., Kurniawan, L. B., & Aprianti, S. (2018) · INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · doi:10.24293/ijcpml.v24i1.1165
Frecuencia y características de obesos con y sin riesgo cardiometabólico
Garmendia, F., Pando, R., & Hernández, M. (2018) · Anales de la Facultad de Medicina · doi:10.15381/anales.v79i1.14586 · Cited by 2
Primary Prevention of Atherosclerotic Cardiovascular Disease
Robinson, J. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00028-5 · Cited by 4
Kodiatte, A. A., & Jacob, J. J. (2018) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20183915
“Very high hypertriglyceridemia (serum triglycerides ˃500mg/dL) (classification of hypertriglyceridemia is mentioned in Table 1) can have grave repercussions on the body.(1,2) It is most frequently associated with a premature coronary artery disease and acute pancreatitis.”
BackgroundThe concept of severe hypertriglyceridaemia and its implications for clinical practice
Pintó, X., & Esteve-Luque, V. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.08.004
An Update on Hypertriglyceridemia-Induced Acute Pancreatitis
Kim, H. J. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.6.518
Very Severe Hypertriglyceridemia-Casre Report with General Considerations
Miulescu, R. D., Tinu, A. M., Margina, D. M., Grădinaru, D., Ungurianu, A., & Guja, L. (2018) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2018-0051
Caron‐Dorval, D. (2014) · Corpus Université Laval (Université Laval)
Xantomas, la pieza clave para el diagnóstico de una hipertrigliceridemia grave
González-Arango, J., Aguirre, H. D., Mejía, A. M., Márquez-Morón, M. D. P., & Zúñiga, E. B. P. (2019) · CES Medicina · doi:10.21615/cesmedicina.33.1.7
Erdem, M., Tüfekçi, Ö., Karapınar, T. H., et al. (2018) · LLM Dergi · doi:10.5578/llm.67562
Acute Pancreatitis in a Pregnant Patient with Type IV Hyperlipoproteinemia
Lee, S., Jun, J. H., Doh, Y. S., Jang, J. W., Kim, S. H., Baek, I. H., & Jung, S. H. (2019) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2019.24.2.73
Hipertrigliseridemiye bağlı akut pankreatit hastalarının acil serviste yönetimi
Uz, İ., Özçete, E., Kodik, M. S., Ersel, M., & Kıyan, S. (2018) · Ege Tıp Dergisi · doi:10.19161/etd.471699
CLINICAL ASSESSMENT OF SERUM TRIGLYCERIDE LEVELS IN PATIENTS SUFFERING FROM DIABETES IN AIIMS, PATNA
Kumar, M. (2019) · International Journal of Medical and Biomedical Studies · doi:10.32553/ijmbs.v3i6.408
“hypertriglyceridemia when reduction of cardiovascular risk is required.[9]”
Background32-Year-Old Man With New Onset Abdominal Pain
Shabtaie, S. A., Codipilly, D. C., & Sweetser, S. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.11.039
“They should not be used as monotherapy for treatment or prevention of severe hypertriglyceridemia.(5) Fibrate medications are most efficacious in reducing triglyceride levels and were prescribed to our patient.”
BackgroundInfluentialCHRONIC INTERACTION BETWEEN METFORMIN AND MELOXICAM IN MICE
Al-Rekabi, F. M. K. (2019) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2019.v12i2.29947
“Very high TG levels also increase the risk of acute pancreatitis [48].”
BackgroundPengaruh Susu Kedelai dan Bubur Kacang Hijau terhadap Lingkar Pinggang Wanita Pascamenopause
Syailawan, F. K., Wiboworini, B., & Kartikasari, L. R. (2019) · Media Kesehatan Masyarakat Indonesia · doi:10.30597/mkmi.v15i3.6267
Korolyuk, O. Y. (2020) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs05.01.125
“Фібриноген, г/л 3,4 [2,8; 4,1] 3,7 [3,0; 4,0] 0,539”
InfluentialJahlan, D. H. A. (2020) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v8i4.91
Xhardo, E., & Agaçi, F. (2020) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.2.2020.201304
“Clinical Practice Guideline published in 2012 about Evaluation and Treatment of Hypertriglyceridemia states that the diagnosis and classification of hypertriglyceridemia based on fasting levels include mild and moderate hypertriglyceridemia (triglycerides of 150– 999 mg/dl), severe hypertriglyceridemia (1,000–1,999 mg…”
BackgroundHypertriglyceridemia-induced Pancreatitis in Pregnancy and Its Management Issues: A Case-based Study
Hanmayyagari, B., Wadwa, J., Guntaka, M., & Krishna, B. (2020) · Apollo Medicine · doi:10.4103/am.am_18_20
The Effects of Induced Polycystic Ovary Syndrome in NAG-1 Transgenic Mice
Werner, N. (2020) · ScholarWorks (Central Washington University)
HYPERTRIGLYCERID-ASSOCIATED ACUTE PANCREATITIS: CLINICAL CHARACTERISTICS AND TREATMENT RESULTS
Onishchenko, M., Shchyhel, I. A., Ivanets, T., Levchenko, L. V., & Gorlach, A. (2020) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.1(115).2020.47-52
Hypertriglycedemic Pancreatitis: Is It Time to Embrace Plasmapheresis?
Limula, C. J., & Ozair, F. (2020) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2020.2.4.472
Pezzilli, R. (2020) · Gastroenterology Insights · doi:10.3390/gastroent11020005
“Environmental factors, alcohol, positive-energy balanced diet, obesity, noncompensated diabetes mellitus, renal diseases, pregnancy, hypothyroidism, and medications such as estrogens, retinoids, thiazides, and b-blockers are responsible for raised triglyceride levels, with possible interactions with genetic factors [8…”
BackgroundKumar, K., Raj, R., & Sattar, F. (2020) · Telangana Journal of Psychiatry · doi:10.18231/j.tjp.2020.007
“Elevated levels of triglycerides are associated with atherosclerosis, even in the absence of hypercholesterolemia and predispose to cardiovascular disease.(28) This unique constitution, described as “hypertriglyceridemic waist” phenotype by Lemieux et al,(29) can be a simple bedside screening instrument for recognizin…”
BackgroundClinical Approach for Patients with Hypertriglyceridemia-Induced Acute Pancreatitis
Kim, S.-H., & Son, B. K. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.6.377
“Fibrate는 중성지방의 이 화작용을 촉진하고 VLDL 분비 및 혈중중성지방을 40-60% 낮추고 고밀도 지방단백(HDL cholesterol) 수치를 높이는 효 과가 있다.”
InfluentialVeltri, N. L., Chan, M., & Awad, S. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.200237-f
Barrera, F. J., Raygoza-Cortez, K., García-Leal, M., Brito, J. P., Ospina, N. S., & Rodríguez‐Gutiérrez, R. (2021) · Endocrine · doi:10.1007/s12020-020-02592-y · Cited by 1
A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks
Saunders, I., & Bain, S. C. (2021) · Diabetic Medicine · doi:10.1111/dme.14539
A Case of very Severe Hypertriglyceridemia during Pregnancy
AYDEMİR, E., ÇETİN, S. B., ÜNSAL, Y. A., Ateş, C., Cander, S., Gül, Ö. Ö., Ertürk, E., & Ersoy, C. (2021) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.882279
Lipemia in Hypertriglyceridemia Induced Acute Pancreatitis
Vasantha Kumar, V. R. R. (2024) · General Medicine Open Access · doi:10.5281/zenodo.12684483
Tsuyama, T., Kaino, S., Fujimoto, Y., et al. (2021) · Suizo · doi:10.2958/suizo.36.150
La hipertrigliceridemia leve a moderada parece incrementar también el riesgo de pancreatitis aguda
Decarlini, M. F. (2017) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v20i2.6767
AN INFANT PRESENTING WITH MILKY SERUM: A RARE CASE REPORT
Varsha, S., Shubha, H. V., Vivek, T. G., & Vijaya, C. (2021) · International Journal of Medical Laboratory Research · doi:10.35503/ijmlr.2021.6209
Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes
Jain, R. K., Olejas, S., Davey, S., et al. (2021) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.9734/bpi/nfmmr/v14/12685d
Hypertriglyzeridämie verstehen: Was ist zu tun? Ist etwas zu tun?
Berent, T., Derfler, K., & Berent, R. (2021) · Der Kardiologe · doi:10.1007/s12181-021-00503-7
Ghosal, S., Naher, B., Noor, M. A., et al. (2021) · KYAMC Journal · doi:10.3329/kyamcj.v12i3.56562
Adviesbasis voor de bemesting van akkerbouwgewassen : bemonstering
van Dijk, W., & van Geel, W. C. A. (2010) · Socio-Environmental Systems Modeling
Sanda, H., Mahamud, B., Patel, S., Meneissy, N., Rehmani, H., Elshowaya, S., & Mlawa, G. (2021) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/1347
“org Page 3 Diagnosis of acute pancreatitis is based on presence of at least 2 of the following factors clinical factors including abdominal pain, elevated pancreatic enzymes and radiologic features of acute pancreatitis [13].”
BackgroundVilla, G. C. F., Owusu, D., Azumah, M., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3978563
Mselle, M., Shayo, A. M., Mbwasi, R. M., Mosha, F., Pyuza, J. J., Mrindoko, P., Peter, N., Meleki, E. R., Kimambo, E., Likiliwike, A., et al. (2021) · Open Journal of Pediatrics · doi:10.4236/ojped.2021.114072
“Hypertriglyceridemia can be mild to borderline high (150 - 199 mg/dl), moderate to high (200 - 499 mg/dl), very high (500 - 999 mg/dl), severe (1000 - 1999 mg/dl) and very severe (>2000 mg/dl) [5] [6] [7] [8] Primary hypertriglyceridemia is due to a genetic defect.”
BackgroundGenetic Forms of Dyslipidaemia
Romeo, S., Angelin, B., & Parini, P. (2022) · doi:10.1093/med/9780198870197.003.0231
Diniz, E. T., Cardoso, A. C. S., & Bandeira, F. A. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_44
Agrawal, P. (2022) · Journal of Gastroenterology Research · doi:10.36959/621/629 · Cited by 2
Primary hypertriglyceridemia induced pancreatitis in a cohort of Pakistani children
Khan, S. A., Khan, A., & Malik, M. I. (2022) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0007 · Cited by 1
Clinical Effects of Inadvertent Increased Lipid Infusion in Neonates
Hulgan, C. M., Snow, T., & Check, J. F. (2022) · Advances in Neonatal Care · doi:10.1097/anc.0000000000000986
Early Phase Metabolic Research with Reference to Special Populations
Morrow, L., & Krentz, A. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_20
Parte I. Fibratos en prevención primaria y secundaria
(2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(16)30083-3
(2020) · International Journal of Biology and Biomedical Engineering · doi:10.46300/91011.2020.14.13
OBSOLETE: Hypertriglyceridemia
Maio, A., & Dowd, F. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05075-3
Clinical Assessment of the Patient with Overweight or Obesity
Crane, J. D., & McGowan, B. M. (2019) · Endocrinology · doi:10.1007/978-3-319-46933-1_19 · Cited by 2
Pancreatitis, pregestational diabetes and hyperchylomicronia in a pregnant woman with COVID-19
Laurijssen, S., Blanchaert, C., Twickler, T. B., & Dam, K. V. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.4.9032
SÍNDROME DA HIPERTRIGLICERIDEMIA: UM RELATO DE CASO
Filho, M. A. G., Bressa, J. A. N., Rosseto, F., Mendes, D. D. P., de Castro, P. M. T., & Bidóia, R. D. L. (2022) · Colloquium Vitae · doi:10.5747/cv.2021.v13.n2.v333
Hypertriglyceridaemia: a commentary
Ryan, A., Simpson, W. G., & Twomey, P. J. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208513
Acute pancreatitis caused by hypertriglyceridemiaPreprint
Nabki, R., & Ali, A. F. (2022) · Research Square · doi:10.21203/rs.3.rs-2170082/v1
Pancréatite aiguë grave du patient adulte en soins critiques 2021
Jaber, S., Garnier, M., Asehnoune, K., Bounes, F. V., Buscail, L., Chevaux, J., Dahyot‐Fizelier, C., Darrivère, L., Jabaudon, M., Joannès-Boyau, O., et al. (2022) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2022.10.004 · Cited by 1
Ulizko, V. M., Slobodyanyuk, T., Kryzhanivsky, V. R., et al. (2022) · Zhytomyr Ivan Franko State University Journal Рedagogical Sciences · doi:10.35433/pedagogy.2(109).2022.221-230
Ramanan, V. E. (2022) · Homœopathic Links · doi:10.1055/s-0041-1739426
Lamsal, D. K., Pant, R., & Sangroula, R. K. (2022) · Journal of Chitwan Medical College · doi:10.54530/jcmc.1158 · Cited by 1
Zaboon, M. A., & Jasim, W. E. (2022) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.12.4.42 · Cited by 1
Jin, J., Hu, X., François, M., Zeng, P., Wang, W., Yu, B., Zhou, Y., & Dong, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2620348/v1
Síndrome de quilomicronemia: aspectos genéticos y revisión de la literatura
Ricardo Fuentes, U., & Rosa Pardo, V. (2022) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2022.68961 · Cited by 2
Severe Hypertriglyceridemia: A 10-Year Review in a Portuguese Hospital
Laranjeira, F. S., Neves, N. M., Raimundo, A., & Horta, A. B. (2023) · Cureus · doi:10.7759/cureus.41239
“As a first-line agent, the European Endocrine Society recommends the use of a fibrate for the reduction of TG levels in patients at risk of hypertriglyceridemia-induced AP because fibrates are the most effective drugs in lowering TG levels [15].”
BackgroundKatahira, M., Imai, S., Ono, S., & Moriura, S. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0045 · Cited by 3
Taneja, V., Shah, D., Dessai, R., et al. (2023) · Annals of African Medicine · doi:10.4103/aam.aam_245_21
Acute Pancreatitis Associated with Metabolic, Infections and Drug‐Related Diseases
Aghdassi, A. A., Wiese, M. L., Tran, Q. T., & Lerch, M. M. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch22
Bhuiyan, M., Pramanik, O., & Badar, F. (2023) · Cureus · doi:10.7759/cureus.44567 · Cited by 1
“Severe elevations in triglyceride levels can be attributed to the use of oral estrogen, tamoxifen, raloxifene, clomiphene, isotretinoin, cyclosporine, sirolimus, capecitabine, propofol, protease inhibitors, and interferon [2,3].”
BackgroundThe relationship between visceral adiposity index and acute pancreatitisPreprint
Wang, T., Cao, F., He, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3415488/v1
Metadata
- Authors
- Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H.
- Affiliations
- University of California, Davis (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Harvard University (US)
- Mayo Clinic (US)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 2969-2989
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3431581
- OpenAlex
- W2111416524
- Cited by
- 887
- References
- 206
- Citations by year
- 2026: 55 · 2025: 54 · 2024: 74 · 2023: 62 · 2022: 72 · 2021: 74 · 2020: 83 · 2019: 61 · 2018: 89 · 2017: 50 · 2016: 62 · 2015: 57 · 2014: 48 · 2013: 41
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Heart Association
- European Society of Endocrinology
- National Heart, Lung, and Blood Institute (R01HL045095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, triglyceride levels, fasting triglycerides, cardiovascular risk, pancreatitis, secondary hyperlipidemia, familial hypertriglyceridemia, dyslipidemia, non-HDL cholesterol, lifestyle therapy, fibrate therapy
- MeSH terms
- Exercise Therapy, Humans, Terminology as Topic, Triglycerides, Hypertriglyceridemia, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.